OTC:TCNNF
Trulieve Cannabis Corp.
A major Florida-based medical cannabis cultivator and retailer with substantial cash holdings and a diversified product portfolio across multiple states.
Key Metrics
Investment Thesis
Bull Case
TCNNF offers compelling value for investors seeking exposure to the legal cannabis industry through its dominant market position in Florida and strong cash reserves exceeding $250 million. The company's revenue stability around $1.18 billion annually combined with improving operating profits ($143.5M) signals potential margin expansion as scale economies take effect. Successful navigations of regulatory complexities could unlock significant growth potential, especially if the company achieves consistent profitability in upcoming fiscal years.
Bear Case
The persistent annual net losses exceeding $100 million raise serious concerns about the company's ability to achieve sustainable profitability without further dilution or debt servicing issues. Heavy reliance on external financing, evidenced by large negative cash flows from investing and financing activities, exposes the stock to liquidity risks if market conditions deteriorate. Investors should be wary of regulatory volatility in Florida and other states, which could disrupt operations and erode the company's competitive moat.
About Trulieve Cannabis Corp.
Trulieve Cannabis Corp. (TCNNF) is a leading medical cannabis cultivation and dispensary operator serving patients across Florida and other regulated markets. The company generates revenue through the sale of flower, concentrates, edibles, and topicals while maintaining a robust network of retail locations. With over $1.1 billion in recent annual revenue and significant cash reserves, TCNNF aims to expand its market share in the competitive legal cannabis sector.
Analysis
Management Discussion
Despite generating $1.18 billion in revenue, the company reported a net loss of $122.2 million, driven by substantial cost of revenue ($470M) and general administrative expenses ($445M). The significant cash outflow from financing activities (-$270.5M) alongside strong operating cash flow ($272.8M) highlights aggressive capital raising or debt restructuring efforts to support growth initiatives. Management's ability to reduce the retained earnings deficit while maintaining positive operating profits suggests a strategic pivot toward profitability, though the path remains challenging given the consistent losses over the last five years.
Industry Overview
The legal cannabis industry is rapidly evolving with increasing state-level legalization creating a fragmented yet expanding market landscape. Companies like Trulieve are positioned to capitalize on this growth through consolidation efforts and economies of scale in cultivation and retail distribution. However, the sector faces ongoing challenges related to banking restrictions, tax policies under IRC 280E, and varying regulatory frameworks across different jurisdictions.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $1.24B | $1.13B | $1.19B | $1.18B |
| Cost of Revenue | $557.8M | $540.6M | $470.7M | $470.0M |
| Gross Profit | $682.0M | $588.6M | $715.7M | $711.2M |
| Operating Expenses | $649.6M | $810.2M | $618.0M | $567.7M |
| Operating Income | $32.4M | $-221.6M | $97.8M | $143.5M |
| G&A | $169.7M | $146.0M | $252.7M | $445.2M |
| Marketing | $284.9M | $240.2M | $257.7M | — |
| Stock-Based Comp | $18.1M | $10.6M | $20.2M | $20.5M |
| D&A | $119.4M | $109.8M | $112.8M | $117.6M |
| Depreciation | $76.4M | — | — | — |
| Amortization | $83.9M | $80.4M | $82.2M | $83.3M |
| Other OpEx | $194.9M | $424.1M | $107.5M | $122.5M |
| Non-Operating Income | $-75.8M | $-62.9M | $-55.1M | $-52.0M |
| Interest Expense | $79.8M | $81.6M | — | — |
| Interest Income | — | $6.2M | $14.7M | $14.5M |
| Pre-Tax Income | $-43.3M | $-284.5M | $42.7M | $91.5M |
| Income Tax | $161.8M | $151.4M | $197.6M | $208.1M |
| Continuing Ops | $-205.2M | $-435.9M | $-154.9M | $-116.6M |
| Discontinued Ops | $-47.6M | $-97.2M | $-5.7M | $-5.6M |
| Net Income | $-252.7M | $-533.1M | $-160.6M | $-122.2M |
| Minority Interest | $-6.7M | $-5.1M | $-5.5M | $-5.9M |
| Net to Common | $-246.1M | $-528.0M | $-155.1M | $-116.4M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $593.0M | $477.3M | $604.6M | $562.7M |
| Cash & Equivalents | $212.3M | $201.4M | $238.8M | $255.5M |
| Marketable Securities | — | — | $60.4M | $0 |
| Accounts Receivable | $9.4M | $6.7M | $8.3M | $10.5M |
| Inventory | $297.8M | $213.1M | $231.4M | $242.3M |
| Prepaid Expenses | $63.6M | — | — | — |
| Other Current Assets | $9.8M | $56.2M | $65.7M | $54.4M |
| Long-Term Assets | $2.81B | $2.25B | $2.27B | $2.13B |
| PP&E (Net) | $796.9M | $676.4M | $716.1M | $670.4M |
| Goodwill | $791.5M | $483.9M | $483.9M | $483.9M |
| Operating Leases | $101.4M | $95.9M | $119.5M | $108.3M |
| Other LT Assets | $1.12B | $995.5M | $946.2M | $870.7M |
| Total Assets | $3.40B | $2.73B | $2.87B | $2.70B |
| Current Liabilities | $209.7M | $114.8M | $138.5M | $126.9M |
| Accounts Payable | $16.4M | $28.2M | $20.2M | $26.8M |
| Current Leases | $10.4M | $10.1M | $12.1M | $13.0M |
| Deferred Revenue | $9.5M | $1.3M | $7.5M | $9.1M |
| Other Current Liab | $173.3M | $75.2M | $98.6M | $78.0M |
| Long-Term Liabilities | $1.26B | $1.21B | $1.48B | $1.43B |
| LT Operating Leases | $102.4M | $92.2M | $117.5M | $107.9M |
| Other LT Liab | $1.16B | $1.11B | $1.37B | $1.32B |
| Total Liabilities | $1.47B | $1.32B | $1.62B | $1.55B |
| Shareholders' Equity | $1.93B | $1.41B | $1.25B | $1.14B |
| Retained Earnings | $-113.8M | $-640.6M | $-795.7M | $-912.1M |
| Total L&E | $3.40B | $2.73B | $2.87B | $2.70B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-252.7M | $-533.1M | $-160.6M | $-122.2M |
| Non-Cash Adjustments | $145.0M | $904.4M | $407.9M | $412.3M |
| Working Capital Changes | $130.8M | $-169.4M | $24.1M | $-17.2M |
| Cash from Operations | $23.1M | $201.8M | $271.5M | $272.8M |
| Capital Expenditures | $164.7M | $40.4M | $121.5M | $44.2M |
| Cash from Investing | $-215.1M | $-37.5M | $-206.6M | $13.5M |
| Cash from Financing | $177.8M | $-175.6M | $-33.4M | $-270.5M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $-14.2M | $-11.2M | $31.4M | $15.8M |
| Beginning Cash | $233.1M | $213.8M | $208.0M | $239.7M |
| Ending Cash | $218.9M | $208.0M | $239.7M | $255.5M |
Frequently Asked Questions
How does Trulieve Cannabis Corp. make money?
The company's operations are segmented by state of operation, primarily focusing on Florida where it holds dominant dispensary licenses. Revenue streams include direct-to-consumer sales of flower products, concentrates, edibles, and topicals sold at retail dispensaries. Additional segments include wholesale distribution to other licensed entities and potential future expansion into recreational markets in states like Colorado or Illinois.
What are the main risks for TCNNF?
Persistent net losses of over $100 million annually indicate ongoing operational inefficiencies or heavy investment phases that may not yield immediate profitability. Regulatory uncertainty remains a critical risk, as state laws can change abruptly, affecting licensing renewals and operational permissions in key markets. High accounts payable balance relative to receivables suggests potential cash flow pressure if inventory turnover slows or collections lag. Competition from new entrants and price wars could further erode gross margins in a market with relatively low barriers for small-scale growers.
What is TCNNF's competitive advantage?
Trulieve benefits from its massive scale as the largest medical cannabis operator in Florida, granting it superior supply chain efficiency and brand recognition among patients. The company maintains a strong balance sheet with over $255 million in cash and equivalents, providing liquidity to navigate regulatory hurdles and fund expansion without dilution. Its diversified product portfolio and extensive retail footprint create high barriers to entry for smaller competitors.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.